NCT04085029
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting

Drug Category: Radiation Therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have planned to receive, currently receiving, or have completed hypofractionated image guided radiotherapy (ablative radiotherapy) to site outside of the brain
Exclusions: 
https://ClinicalTrials.gov/show/NCT04085029